Avila Therapeutics, a biotechnology company developing targeted covalent drugs, has named Andrew Hirsch its first chief financial officer.

"As we continue to drive drug development programs arising from the Avilomic platform into the clinic, Andrew's nearly 20 years in corporate finance and strategic management will be a tremendous asset to Avila. His breadth of experience provides us with key insights into successfully creating value as we advance our drug candidates and grow as an organization," said Katrine Bosley, CEO of Avila.

Hirsch joins Avila from Biogen Idec, where he spent the past 10 years in a number of roles, most recently as vice president of corporate strategy and M&A. Previously, he led business development for a software startup and spent several years in management consulting at Stern Stewart and The Parthenon Group.